Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Goodwill (2016 - 2022)

Historic Goodwill for Sangamo Therapeutics (SGMO) over the last 10 years, with Q4 2022 value amounting to $37.6 million.

  • Sangamo Therapeutics' Goodwill fell 541.53% to $37.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $37.6 million, marking a year-over-year decrease of 541.53%. This contributed to the annual value of $37.6 million for FY2022, which is 541.53% down from last year.
  • As of Q4 2022, Sangamo Therapeutics' Goodwill stood at $37.6 million, which was down 541.53% from $34.5 million recorded in Q3 2022.
  • In the past 5 years, Sangamo Therapeutics' Goodwill ranged from a high of $42.8 million in Q4 2020 and a low of $1.6 million during Q1 2018
  • Moreover, its 5-year median value for Goodwill was $39.3 million (2019), whereas its average is $33.7 million.
  • Its Goodwill has fluctuated over the past 5 years, first surged by 242643.53% in 2018, then crashed by 1485.07% in 2022.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Goodwill stood at $40.0 million in 2018, then decreased by 1.93% to $39.3 million in 2019, then increased by 8.98% to $42.8 million in 2020, then fell by 7.23% to $39.7 million in 2021, then decreased by 5.42% to $37.6 million in 2022.
  • Its Goodwill stands at $37.6 million for Q4 2022, versus $34.5 million for Q3 2022 and $36.7 million for Q2 2022.